Deborah Doroshow, MD, PhD
Assistant Professor AdjunctCards
Appointments
Additional Titles
Academic Affiliate in the History of Medicine
Contact Info
Appointments
Additional Titles
Academic Affiliate in the History of Medicine
Contact Info
Appointments
Additional Titles
Academic Affiliate in the History of Medicine
Contact Info
About
Titles
Assistant Professor Adjunct
Academic Affiliate in the History of Medicine
Biography
Deborah Doroshow is Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Adjunct Assistant Professor of the History of Medicine at the Yale University School of Medicine.
She graduated from Harvard College in 2004 with a B.A. in History and Science, where she wrote a senior thesis entitled "The Injection of Insulin Into American Psychiatry," which explored the history of insulin coma therapy for schizophrenia. It was awarded the Thomas Temple Hoopes Award for outstanding senior thesis, and a portion of it was subsequently published in the Journal of the History of Medicine and Allied Sciences.
She earned her Ph.D. in History with distinction (concentration in the History of Science and Medicine) from Yale University in December 2012, winning the Edwin W. Small prize for outstanding dissertation in American History and the Pressman Career Development Award from the American Association of the History of Medicine. Her book, Emotionally Disturbed: A History of Caring for America's Troubled Children, was published by the University of Chicago Press in 2019.
Additional historical work has included a study of bedwetting alarms and parenting practices in mid-twentieth century America (Isis, 2010) and a history of laws mandating premarital syphilis testing (Social History of Medicine, 2019). She is an active member of the American Association for the History of Medicine and enjoys mentoring clinician-historians in training.
Deborah earned her M.D. from Harvard Medical School in 2013. She completed her internship and residency in internal medicine at the Yale University School of Medicine in 2015 and her fellowship in hematology and oncology, also at Yale, in 2019. At Mount Sinai, she treats adults with lung cancer as well as adults with a variety of solid tumors as part of the Early Phase Trials Unit, where her work focuses on the DNA damage response.
Appointments
History of Medicine
Assistant Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- Resident
- Yale University School of Medicine (2015)
- MD
- Harvard Medical School (2013)
- PhD
- Yale University, History (2012)
- AB
- Harvard College, History and Science (2004)
Research
Overview
Medical Subject Headings (MeSH)
ORCID
0000-0002-2221-9818
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Nelson LaMarche, PhD
Lung Neoplasms
Publications
2024
EP.06D.04 Prognostic Value of Variant Allele Frequency in Circulating Tumor DNA for Survival Outcomes in Metastatic Non-Small Cell Lung Cancer
Peleg A, de la Fuente R, Lichtman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Rohs N, Smith C, Rolfo C. EP.06D.04 Prognostic Value of Variant Allele Frequency in Circulating Tumor DNA for Survival Outcomes in Metastatic Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s502-s503. DOI: 10.1016/j.jtho.2024.09.932.Peer-Reviewed Original ResearchP3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
de la Fuente R, Peleg A, Litchman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Smith C, Rohs N, Rolfo C. P3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s323. DOI: 10.1016/j.jtho.2024.09.579.Peer-Reviewed Original ResearchAn updated comparative analysis of needs and role of patient navigation among early phase cancer clinical trial participants and non-participants at a single cancer center.
Doroshow D, Sheng T, Aryeh B, Conner R, Loehle J, Lucas N, Padilla M, Pappalardo R, Fromm K, Smith C. An updated comparative analysis of needs and role of patient navigation among early phase cancer clinical trial participants and non-participants at a single cancer center. Journal Of Clinical Oncology 2024, 20: 237-237. DOI: 10.1200/op.2024.20.10_suppl.237.Peer-Reviewed Original ResearchConceptsSDoH barriersEarly phase clinical trialsCancer clinical trial participationSocial drivers of healthDrivers of healthHealth care systemClinical trial participationClinical trialsPatient navigationFinancial toxicitySDoHSymptom burdenCare systemImprove participationNeeds assessmentDiagnosis to treatmentDescriptive characteristicsPhase clinical trialsTrial participantsLevel of acceptanceLonger visitsVulnerable populationsNon-participantsTreatment adherenceScreening visit632P Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Lin C, Schneider R, Gutierrez M, Shen L, Chung K, Doroshow D, Gao B, Millward M, Hsieh C, Xu C, Cai S, Tian Y, Liu L, Shen C, Tan Y, He Y, Zhang C, Li L, Ma M, Xu L. 632P Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors. Annals Of Oncology 2024, 35: s503-s504. DOI: 10.1016/j.annonc.2024.08.699.Peer-Reviewed Original ResearchPeripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis
Karol A, Fujiwara Y, D'Ovidio T, Baldwin E, Joshi H, Doroshow D, Galsky M. Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis. Immunotherapy 2024, 16: 829-840. PMID: 39155854, PMCID: PMC11457654, DOI: 10.1080/1750743x.2024.2379230.Peer-Reviewed Original ResearchAltmetricConceptsImmune checkpoint blockadeProgression-free survivalC-reactive proteinPeripheral blood cytokinesOverall survivalTumor-promoting inflammationCheckpoint blockadeInterleukin-6Interleukin-8Blood cytokinesOn-treatment declineIL-8 levelsTrial end pointsIL-6 levelsPharmacodynamic biomarkersInflammatory cytokinesEnd pointsResponse rateCytokinesMeta-analysisSystematic reviewBlockadeInflammationORRSurvivalA comparative analysis of needs and role of patient navigation among early-phase cancer clinical trial participants and non-participants at a single cancer center.
Doroshow D, Sheng T, Aryeh B, Conner R, Loehle J, Lucas N, Padilla M, Pappalardo R, Fromm K, Smith C. A comparative analysis of needs and role of patient navigation among early-phase cancer clinical trial participants and non-participants at a single cancer center. Journal Of Clinical Oncology 2024, 42: e23127-e23127. DOI: 10.1200/jco.2024.42.16_suppl.e23127.Peer-Reviewed Original ResearchConceptsSDoH barriersEarly phase clinical trialsCancer clinical trial participationSocial drivers of healthDrivers of healthHealth care systemClinical trial participationPatient navigationNavigation interventionClinical trialsFinancial toxicityIdentified barriersCare systemSDoHImprove participationNeeds assessmentDiagnosis to treatmentDescriptive characteristicsTrial participantsLevel of acceptanceVulnerable populationsNon-participantsPhase clinical trialsTreatment adherenceScreening visitTrastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).
Oh D, Lugowska I, Stroyakovskiy D, Jung K, Dumas O, Penkov K, Dechaphunkul A, Oaknin A, Kim S, Starling N, Chewaskulyong B, Charonpongsuntorn C, Doroshow D, Hsiao S, Hung Y, Jung L, Kuptsova-Clarkson N, Michelini F, Puvvada S, Meric-Bernstam F. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). Journal Of Clinical Oncology 2024, 42: 4090-4090. DOI: 10.1200/jco.2024.42.16_suppl.4090.Peer-Reviewed Original ResearchCitationsConceptsBiliary tract cancerProgression-free survivalT-DXdPancreatic cancerHER2 expressionEfficacy outcomesDrug-related interstitial lung diseaseOpen-label phase 2 studyPC cohortDrug-related adverse eventsLate-line treatmentPrimary tumor locationPhase 2 studyGrade (GClinically meaningful benefitInterstitial lung diseaseHER2-expressing tumorsAdvanced/metastatic diseaseData cutoffIHC 3PD-L1Trastuzumab deruxtecanExploratory endpointsTumor locationPrimary endpointEfficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
Wysocki P, Jung K, Oh D, Doroshow D, Artamonova E, Mammatas L, SU P, Moiseyenko V, Penkov K, Stroyakovskiy D, Bartolome J, Siena S, Fielding A, Jung L, Michelini F, Puvvada S, Makker V. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study. Journal Of Clinical Oncology 2024, 42: 4565-4565. DOI: 10.1200/jco.2024.42.16_suppl.4565.Peer-Reviewed Original ResearchCitationsConceptsDisease control rateProgression-free survivalDuration of responseT-DXdPretreated ptsHER2 expressionUrothelial cancerBladder cohortEfficacy outcomesSolid tumorsSafety of trastuzumab deruxtecanDrug-related adverse eventsPhase 2 studyClinically meaningful responseGrade (GHER2 expression levelsTrastuzumab deruxtecanAdvanced/metastatic diseaseData cutoffPD-L1Open-labelExploratory endpointsPrimary endpointSystemic treatmentSecondary endpointsOptimizing care in early phase cancer trials: The role of palliative care
Crowley F, Sheppard R, Lehrman S, Easton E, Marron T, Doroshow D, Afezolli D. Optimizing care in early phase cancer trials: The role of palliative care. Cancer Treatment Reviews 2024, 128: 102767. PMID: 38776612, DOI: 10.1016/j.ctrv.2024.102767.Peer-Reviewed Original ResearchAltmetricConceptsPalliative care interventionsPalliative careCare interventionsSymptom managementUnique palliative care needsPalliative care needsPalliative care workforcePhysical symptom managementPalliative care approachAdvance care planningHome-based interventionClinical trial participationPsychological well-beingCare planningCare workforceCare needsCare utilizationCare approachSpiritual supportOptimal careIncreased length of timeTrial participantsIntervention studiesEarly phase clinical trialsCareC-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis
Fujiwara Y, Karol A, Joshi H, Reford E, Izadmehr S, Doroshow D, Galsky M. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews In Oncology/Hematology 2024, 197: 104352. PMID: 38614269, PMCID: PMC11219184, DOI: 10.1016/j.critrevonc.2024.104352.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsProgression-free survivalC-reactive proteinUrothelial carcinomaTumor-promoting inflammationOverall survivalCRP valuesHazard ratioPro-inflammatory tumor microenvironmentAssociated with shorter OSICB-treated patientsImmune checkpoint blockadeEvaluate survival outcomesRandom-effects model meta-analysesHigher CRP levelsSystematic reviewMeta-analysesLow CRP valuesCheckpoint blockadeShorter OSSurvival outcomesTumor microenvironmentCRP levelsPrognostic biomarkerCarcinomaPatients